OVERCOMING SCIENCE’S HARDEST OBSTACLES IS OUR HIGHEST PRIORITY

Helen is a retired senior executive with a 30-year career in the biotech, pharmaceutical, consulting, and banking industries. Most recently, Helen served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech. Over the course of her career, she held positions of increasing scope and responsibility in finance in the biotech and pharmaceutical industries, including Chief Financial Officer of Proteostasis Therapeutics, Chief Financial Officer of FORMA Therapeutics, Chief Financial Officer of Novartis Corporation US, and Chief Financial Officer Global Oncology, Novartis. Prior to Novartis, Helen held positions of increasing responsibility in strategy and finance at Pfizer Inc., including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Helen worked earlier in her career at PepsiCo Inc./YUM! Brands, Inc., McKinsey & Company, and Bank of America Corporation. She currently serves as a board member of Premier, Inc. and Shattuck Labs Inc. Helen previously served on the Board of Directors of Cara Theraputics, Evaxion Biotech A/S, Proteostasis Therapeutics, Inc., and Reunion Neuroscience Inc.

Helen earned a B.A. in economics from the University of Maryland, where she graduated summa cum laude, and an M.B.A. from the Darden Graduate School of Business at the University of Virginia.

Wendy is a board certified clinical and molecular geneticist with more than 20 years of experience in human genetic research. Wendy is currently the Kennedy Family Professor of Pediatrics in Medicine and Director of Clinical Genetics at Columbia University. She is also the Director of Precision Medicine Resource in the Irving Institute and the National Organization for Rare Disorders Center of Excellence at Columbia University. She has authored over 600 peer reviewed papers and 75 reviews and chapters in medical texts. She was the recipient of the Medical Achievement Award from Bonei Olam, the Dade County Hall of Fame, the NY Academy of Medicine Medal for Distinguished Contributions in Biomedical Science, the Rare Impact Award from the National Organization for Rare Disorders and is a member of the National Academy of Medicine. Wendy is a member of the Scientific Advisory Board for Sage Bionetworks, Taysha, Helix, and Regeneron Genetics Center.

Wendy earned a B.A. in Biochemistry and Economics from Cornell University, a M.D. from Cornell University Medical College, and a Ph.D. in Genetics from The Rockefeller University.

Rob is a Managing Partner at Pivotal bioVenture Partners LLC, where he focuses on drug discovery and development investments. He has a long track record of working successfully with entrepreneurs to progress novel, important medicines through development and onto the market. Prior to Pivotal, Rob served as a Principal at Bay City Capital LLC. He previously held business development and investment roles at DuPont Pharmaceuticals and Ag-West Biotech LLC. Rob started his career as a pharmacist after completing his post-doctoral work at Harvard Medical School. Rob currently serves as a board member of Vaxcyte, Inc. and Inozyme Pharma, Inc., and on the boards of a number of private life sciences companies.

Rob earned a B.Sc. in pharmacy and a Ph.D. in pharmacology from the University of Saskatchewan and an MBA from the University of Chicago Booth School of Business.

Ron is a Managing Director at New Leaf Venture Partners, where he focuses on early- to late-stage investments in biopharmaceuticals. He was one of the founders of New Leaf in 2005, and today has over two decades of experience investing in and building companies focused on developing novel medicines that address important unmet medical needs. Prior to New Leaf, Ron was a partner at the Sprout Group, a venture capital firm, and was a consultant with Coopers & Lybrand Consulting and The Health Care Group, Inc. He previously held various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Ron currently serves on the board of directors of Iterum Therapeutics, Ltd. and previously served on the board of directors of Harpoon Therapeutics, Inc. Ron is also on the boards of a number of private pharmaceutical companies. He previously served on the board of directors of Neuronetics, Inc., a medical device company.

Ron earned a B.S. from Cornell University and an MBA from the Wharton School of the University of Pennsylvania.

Lucian is a Managing Director with TPG Growth, where he focuses on healthcare investing. Prior to TPG, Lucian served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. He was also a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. Previously, Lucian worked at McKinsey & Company in the North American healthcare practice, advising on clinical- and business-model transformation for large hospital systems. Lucian is a board-certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company.

Lucian earned both his bachelor’s degree in economics and an M.D. from Tufts University.

Hui is a seasoned biopharma executive with 25 years of experience in business development, finance, and strategy. He is currently the Executive Vice President, Chief Business Officer and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company engaged in developing multispecific antibody therapeutics. Prior to Merus, Hui was the Global Head of Business Development & Licensing at Novartis Oncology. Prior to this, he served as Global Head of Business Development and Licensing for Novartis Vaccines & Diagnostics. Hui began his pharma career in business development at Pfizer where he held roles of increasing responsibility. Prior to Pfizer, he worked in investment banking at Citigroup and Goldman Sachs.

Hui earned a B.S. in biology from Peking University in Beijing, China and both an M.B.A. in finance and Ph.D. in molecular biology from the University of Michigan.

Martin is a Co-Founder and Chairman of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories, Novo Nordisk and Springworks Therapeutics. He is also a Scientific Advisor at Pivotal BioVenture Partners and on the External Advisory Board of Boston Children’s Hospital. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.

Martin obtained a First-Class Honors Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.

Christine is a marketing and commercial executive with 20 years of experience in emerging biopharmaceutical companies. As Principal at Chatiemac Consulting, LLC, she provides strategic and commercial planning guidance to biotechnology companies developing medications for rare diseases. Christine also currently serves as Board Chair and senior advisor to the President and CEO at The CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies. Previously, Christine was at Hyperion Therapeutics, Inc., where she held roles of increasing responsibility in marketing and business development, including Chief Commercial Officer, until Hyperion’s acquisition by Horizon Pharma. Prior to Hyperion, Christine held marketing roles at Cotherix, Inc., until its acquisition by Actelion. Early in her career, she was a Product Manager at Genesoft Pharmaceuticals until its acquisition by Oscient Pharmaceuticals.

Christine earned both a B.A. with honors in public policy and an M.B.A. from Stanford University.

Paula currently serves as lead independent director of the Board. Paula has more than 30 years of rare disease biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation, and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, transplant, and oncology. Paula previously served as founding CEO and member of the Board of Directors of Akcea Therapeutics. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. where she led key strategic alliances and built preclinical programs. Before Moderna, Paula spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. She currently serves as Executive Chairman of Ensoma and as a member of the Board of Directors of uniQure. Paula also serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.

Paula earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia.

Steve is a Co-Founder and Chief Executive Officer of Rallybio. He has more than 25 years of experience, serving in R&D leadership roles with prominent global pharmaceutical and biotech firms. Steve was previously Head of Research at Alexion Pharmaceuticals, where he led a series of collaborations and external alliances, and expanded its research base beyond antibodies to include small molecules, RNA-based therapies and broader protein engineering capabilities. Prior to Alexion, Steve led research and development groups in Japan for Wyeth and Novartis Oncology, and held positions of increasing responsibility at Pfizer in the U.K., Japan and the U.S.

Steve received his medical training at the University of London’s St. Thomas’ Hospital Medical School, and then practiced clinical and academic medicine within the U.K.’s National Health Service and at the University of Manchester.